Fmoc-Dap(Boc)-OH | 130851-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-Dap(Boc)-OH
• 英文别名: DL-Fmoc-Dap(Boc)-OH；2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 130851-23-9
• 化学式: C₂₃H₂₆N₂O₆
• mdl: MFCD00270355
• 分子量: 426.469
• InChiKey: PKAUMAVONPSDRW-UHFFFAOYSA-N

物化性质

• 沸点：
  652.5±55.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.347
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Fmoc-Dap(Boc)-OH 在 caesium carbonate 、 三乙胺 、 三氟乙酸 、 potassium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  一种亲水碳酸酯型抗体偶联药物

  摘要：

  本发明提供一种亲水碳酸酯型抗体药物偶联物或其药学上可接受的盐。本发明提供的亲水碳酸酯型抗体药物偶联物或其药学上可接受的盐，可在肿瘤弱酸性微环境中有效释放药物，获得对肿瘤更好的体内药效，可在高DAR下获得很好的体内PK。

  公开号：

  CN111001012A
• 作为产物：
  描述：

  BOC-L-天冬酰胺 、 9-芴甲基-N-琥珀酰亚胺基碳酸酯 在 吡啶 、 sodium hydroxide 、 碳酸氢钠 、 [双(三氟乙酰氧基)碘]苯 作用下， 生成 Fmoc-Dap(Boc)-OH
  参考文献：
  名称：

  Potent and prolonged-acting cyclic lactam analogs of .alpha.-melanotropin: design based on molecular dynamics

  摘要：

  Utilizing results from previous structure-activity relationships and theoretical studies of alpha-melanotropin (alpha-MSH, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its related superpotent analogues, Ac-[Nle4,D-Phe7]-alpha-MSH and Ac-[Cys4,Cys10]-alpha-MSH, we have designed a new class of alpha-MSH4-13 and alpha-MSH4-10 cyclic lactam fragment analogues of alpha-melanotropin. The cyclic peptides have the following general structures: Ac-[Nle4,Xxx5,D-Phe7,Yyy10,Gly11]-alpha-MSH4-13- NH2 and Ac-[Nle4,Xxx5,D-Phe7,Yyy10]-alpha-MSH4-10-NH2, where Xxx = Glu or Asp and Yyy = Lys, Orn, Dab, or Dpr. Formation of the lactam bridge between the side-chain groups Xxx and Yyy was performed either in solution or on a solid-phase support. Seven cyclic peptides were prepared and bioassayed for their melanotropic potency by using standard frog (Rana pipiens) and lizard (Anolis carolinensis) skin bioassays. Relative to alpha-MSH (relative potency = 1), the potencies of the cyclic peptides in the lizard skin bioassay were as follows: alpha-MSH (1); Ac-[Nle4,Glu5,D-Phe7,Lys10,Gly11]-alpha-MSH4-13- NH2 (6); Ac-[Nle4,Asp5,D-Phe7,Lys10,Gly11]-alpha-MSH4-13- NH2 (100); Ac-[Nle4,Glu5,D-Phe7,Lys10]-alpha-MSH4-10-NH2 (9); Ac-[Nle4,Asp5,D-Phe7,Lys10]-alpha-MSH4-10-NH2 (90); Ac-[Nle4,Asp5,D-Phe7,Orn10]-alpha-MSH4-10-NH2 (20); Ac-[Nle4,Asp5,D-Phe7,Dab10]-alpha-MSH4-10-NH2 (5); Ac-[Nle4,Asp5,D-Phe7,Dpr10]-alpha-MSH4-10-NH2 (5). Similar results were obtained in the frog skin bioassay, but the analogues were much less potent. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher melanotropic potency than alpha-MSH with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins from 23 diminishes the biological potency of the resulting cyclic peptide. The 23- and 24-membered ring analogues showed prolonged (residual) biological activities in both biological assays, but the smaller ring systems (20, 21, 22) did not. These results provide new insights into the structural and conformational requirements of alpha-MSH and its analogues at two different types of pigment cell (melanocyte) receptors.

  DOI：

  10.1021/jm00132a010

文献信息

• [EN] NOVEL IMIDAZOPYRAZINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOPYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021249896A1

  公开（公告）日：2021-12-16

  The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein (formula (I)) or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  这项发明提供了具有一般式(I)的新型咪唑吡嗪衍生物，其中Rx和R3至R5如本文所述（式(I)）或其药学上可接受的盐。还提供了包括这些化合物的药物组合物、制造这些化合物的方法以及将这些化合物用作药物的方法，特别是将这些化合物用作抗生素治疗或预防细菌感染及由此导致的疾病的方法。
• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• Design, synthesis and biological evaluation of TAR and cTAR binders as HIV-1 nucleocapsid inhibitors
  作者：Alice Sosic、Francesco Frecentese、Elisa Perissutti、Laura Sinigaglia、Vincenzo Santagada、Giuseppe Caliendo、Elisa Magli、Antonio Ciano、Giuseppe Zagotto、Cristina Parolin、Barbara Gatto

  DOI：10.1039/c3md00212h

  日期：——

  We designed, synthesized and tested novel 2,6-disubstituted-anthraquinones able to bind dynamic secondary structures of nucleic acids, such as TAR RNA and its reverse transcript cTAR, leading to inhibition of the chaperone activities of the nucleocapsid NCp7, a highly conserved viral protein implied in crucial steps of HIV-1 replication.

  我们设计，合成和测试了能够结合核酸的动态二级结构（例如TAR RNA及其逆转录cTAR）的新型2,6-二取代蒽醌，从而抑制了高度保守的病毒核衣壳NCp7的伴侣活性。蛋白暗示HIV-1复制的关键步骤。
• [EN] SMALL MOLECULE INHIBITION OF MICRO-RNA-210 REPROGRAMS AN ONCOGENIC HYPOXIC CIRCUIT<br/>[FR] L'INHIBITION DU MICRO-ARN-210 PAR DE PETITES MOLÉCULES REPROGRAMME UN CIRCUIT HYPOXIQUE ONCOGÈNE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2018152414A1

  公开（公告）日：2018-08-23

  Herein, we describe the identification of a small molecule named Targapremir-210 that binds to the Dicer site of the miR-210 hairpin precursor. This interaction inhibits production of the mature miRNA, de-represses glycerol-3-phosphate dehydrogenase 1-like enzyme (GPD1 L), a hypoxia-associated protein negatively regulated by miR-210, decreases HIF-1 a, and triggers apoptosis of triple negative breast cancer cells only under hypoxic conditions. Further, Targapremir-210 inhibits tumorigenesis in a mouse xenograft model of hypoxic triple negative breast cancer. We applied Chemical Cross-Linking and Isolation by Pull Down (Chem-CLIP) to study the cellular selectivity and the on- and off-targets of Targapremir-210. Targapremir-210 selectively recognizes the miR-210 precursor and can differentially recognize RNAs in cells that have the same target motif but have different expression levels, revealing this important feature for selectively drugging RNAs for the first time.

  在此，我们描述了一种名为Targapremir-210的小分子的鉴定，它与miR-210毛发前体的Dicer位点结合。这种相互作用抑制了成熟miRNA的产生，解除了由miR-210负调节的与缺氧相关的甘油-3-磷酸脱氢酶1样酶（GPD1 L）的抑制作用，降低了HIF-1 a，并仅在缺氧条件下触发三阴性乳腺癌细胞的凋亡。此外，Targapremir-210抑制了缺氧三阴性乳腺癌小鼠异种移植模型的肿瘤发生。我们应用化学交联和拉下分离（Chem-CLIP）来研究Targapremir-210的细胞选择性以及其靶标和非靶标。Targapremir-210有选择性地识别miR-210前体，并可以不同地识别具有相同靶标基序但表达水平不同的细胞中的RNA，这是首次揭示了这一重要特征，以选择性地药物治疗RNA。